ClinicalTrials.gg
CompletedNCT06964841Updated May 9, 2025

PRIMARY TESTICULAR LYMPHOMA

An observational study in Testicular Lymphoma, sponsored by Instituto Mexicano del Seguro Social. Completed at 1 site in Mexico. Open to male participants. Per ClinicalTrials.gov, last updated 2025-05-09.

Sponsored by Instituto Mexicano del Seguro Social · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
1
Sex
Male
01

Study summary

742 / 5.000 A 57-year-old male: Denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. He denies a family history of testicular cancer or abnormalities in testicular descent.

The patient presented with an enlarged right testicle that had been present for 1 month. He saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. Upon examination, the right testicle was palpable, nontender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa.

The left testicle was normal.

He underwent radical orchiectomy, which revealed renal testicular lymphoma.

Read the detailed description

A 57-year-old male: Denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. He denies a family history of testicular cancer or abnormalities in testicular descent.

The patient presented with an enlarged right testicle that had been present for 1 month. He saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. Upon examination, the right testicle was palpable, non-tender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa.

The left testicle was normal.

He underwent radical orchiectomy, which revealed renal-testicular lymphoma.

On the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord.

He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a 6 cm bleeding gastric ulcer. A biopsy was taken and a diffuse B-cell lymphoma was detected.

He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion.

On the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord.

He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion.

The patient continued to have melena and grade IV anemia. He was referred to pathology, where he was found to have OMS. He showed no improvement despite blood transfusions. He died. Immunohistochemistry for both testicular lesions and on the third postoperative day.

02

Conditions studied

  • Testicular Lymphoma

Browse trials for

Keywords

  • testis
  • lymphoma
  • nodal
  • stomach
03

In context

Lymphoma

5,623 studies on the registry are indexed under Lymphoma; 823 are open to participants now.

This study's enrollment of 1 is below the median of 138 across 633 observational studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

Instituto Mexicano del Seguro Social is the lead sponsor of 125 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

57 year old male with testicular lymphoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with testicular lymphoma

Exclusion criteria

Exclusion Criteria:

  • Patient without testicular lymphoma
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
1 participant (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Mortality

    Describe the mortality in primary testicular lymphoma

    Time frame: 3 months

07

Study locations

1 site
  • Instituto Mexicano del Seguro Social
    Mérida, Yucatán, Mexico
08

References and documents

Publications

  • Motyckova M, Vosahlova V, Belada D, Simkovic M, Zak P. [Primary testicular lymphoma]. Vnitr Lek. 2017 Summer;63(6):415-422. Czech. PubMed 28840738 ↗

Individual participant data

Plan to share: Yes — anyone who ask via e-mail

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: anytime

Access criteria: e-mail

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Mar 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2025
First posted
May 9, 2025
StartActual
Jan 1, 2025
Primary completionActual
Mar 28, 2025
CompletionActual
Mar 29, 2025
Last update
May 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06964841
Responsible party
Huber Díaz Fuentes (PHD, Instituto Mexicano del Seguro Social) — Principal investigator
First posted
May 9, 2025
Start date
Jan 1, 2025
Primary completion
Mar 28, 2025
Completion
Mar 29, 2025
Last update
May 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion